ValuEngine Upgrades Aldeyra Therapeutics (NASDAQ:ALDX) to “Buy”

Aldeyra Therapeutics (NASDAQ:ALDX) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, ValuEngine reports.

ALDX has been the topic of several other reports. Zacks Investment Research upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research report on Wednesday, August 12th. Janney Montgomery Scott reissued a “market perform” rating and set a $28.00 price objective on shares of Aldeyra Therapeutics in a report on Tuesday, May 26th. Citigroup cut their price objective on Aldeyra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Laidlaw reissued a “buy” rating and set a $30.00 price objective on shares of Aldeyra Therapeutics in a report on Tuesday, May 26th. Finally, BidaskClub lowered Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 2nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Aldeyra Therapeutics presently has an average rating of “Buy” and a consensus target price of $22.58.

Shares of Aldeyra Therapeutics stock opened at $7.11 on Tuesday. The stock’s 50-day simple moving average is $6.73 and its 200 day simple moving average is $4.49. Aldeyra Therapeutics has a 52-week low of $1.48 and a 52-week high of $8.05. The stock has a market capitalization of $274.68 million, a P/E ratio of -4.06 and a beta of 2.17. The company has a debt-to-equity ratio of 0.26, a quick ratio of 14.52 and a current ratio of 14.52.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.09. Equities research analysts forecast that Aldeyra Therapeutics will post -1.27 EPS for the current fiscal year.

In other news, major shareholder Perceptive Advisors Llc bought 3,200,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was acquired at an average price of $4.25 per share, with a total value of $13,600,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.00% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its stake in Aldeyra Therapeutics by 1.9% during the 1st quarter. BlackRock Inc. now owns 1,614,192 shares of the biotechnology company’s stock valued at $3,988,000 after purchasing an additional 29,567 shares during the period. Private Advisors LLC raised its stake in Aldeyra Therapeutics by 55.4% during the 1st quarter. Private Advisors LLC now owns 137,230 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 48,916 shares during the period. Acadian Asset Management LLC raised its stake in Aldeyra Therapeutics by 559.5% during the 1st quarter. Acadian Asset Management LLC now owns 33,098 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 28,079 shares during the period. JPMorgan Chase & Co. raised its stake in Aldeyra Therapeutics by 756.6% during the 1st quarter. JPMorgan Chase & Co. now owns 63,340 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 55,946 shares during the period. Finally, Spark Investment Management LLC bought a new stake in Aldeyra Therapeutics during the 1st quarter valued at approximately $40,000. 37.91% of the stock is owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Read More: How To Calculate Debt-to-Equity Ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.